Filip Janku

Internal Medicine

Credentials: · · ·

History

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Review · Blood · 2016 · 1,128 citations
Targeting the PI3K pathway in cancer: are we making headway?
Review · Nature Reviews Clinical Oncology · 2018 · First of 3 authors · 844 citations
Autophagy as a target for anticancer therapy
Review · Nature Reviews Clinical Oncology · 2011 · First of 4 authors · Corresponding · 686 citations

Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)
National Cancer Institute · R01
PI · $1.3M · University of Tx Md Anderson Can Ctr
2019–2024
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $1M · University of Tx Md Anderson Can Ctr
1996–2024

Study of Oral PQR309 in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
PIQUR Therapeutics AG
2019
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Principal investigator · Withdrawn · Phase 2
National Cancer Institute (NCI)
2019–2021
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Principal investigator · Completed · Phase 1, Phase 2
Fujifilm Pharmaceuticals U.S.A., Inc.
2016–2020
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2014–2020